IBM Watson and Quest Diagnostics, which recently partnered with New York’s Memorial Sloan Kettering Cancer Center, have announced the launch of Watson Genomics from Quest Diagnostics.
The program makes use of Watson for Genomics to provide physicians with information to aid in identifying the right individualized treatments for specific cancers. Since cancer treatment is constantly evolving, the program will help physicians stay up to date and provide their patients with the most pertinent treatments for their specific diagnoses.
Under the new service, doctors would send Quest a patient’s tissue sample so that it can be genetically sequenced. This genomic information would then be fed to Watson, using its supercomputing powers and Sloan Kettering’s oncology precision medicine database to sift through the latest cancer research and drug trials.
According to IBM, physicians who work with Quest provide 70% of cancer care in the United States.